Amalgamated Bank Reduces Holdings in Certara, Inc. (NASDAQ:CERT)

Amalgamated Bank lessened its position in shares of Certara, Inc. (NASDAQ:CERT) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,804 shares of the company’s stock after selling 1,130 shares during the period. Amalgamated Bank’s holdings in Certara were worth $496,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CERT. Mubadala Investment Co PJSC purchased a new position in shares of Certara during the 4th quarter valued at $169,135,000. Wasatch Advisors LP lifted its position in shares of Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after buying an additional 932,598 shares during the last quarter. Norges Bank purchased a new position in shares of Certara during the 4th quarter valued at $14,262,000. Geneva Capital Management LLC lifted its position in shares of Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after buying an additional 579,349 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ CERT opened at $11.75 on Monday. The firm has a market capitalization of $1.89 billion, a P/E ratio of -30.13, a P/E/G ratio of 5.17 and a beta of 1.49. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock’s 50-day simple moving average is $12.73 and its two-hundred day simple moving average is $15.06. Certara, Inc. has a twelve month low of $10.35 and a twelve month high of $19.87.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. Certara’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. As a group, equities analysts anticipate that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of recent research reports. KeyCorp dropped their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Robert W. Baird dropped their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barclays dropped their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JMP Securities reissued a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $17.79.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.